Evita Sadimin

Renal cell carcinoma: the search for a reliable biomarker

Nicholas Farber, Christopher J. Kim, Parth K. Modi et al. · Translational Cancer Research · 2017 · 113 citations · Full text

Medicine, Oncology, Pathology +16

Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration

Mark N. Stein, Jyoti Malhotra, Rohinton S. Tarapore et al. · Journal for ImmunoTherapy of Cancer · 2019 · 72 citations · Full text

Medicine, Oncology, Pharmacology +17

Type III Interferon-Mediated Signaling Is Critical for Controlling Live Attenuated Yellow Fever Virus Infection <i>In Vivo</i>

Florian Douam, Yentli E. Soto Albrecht, Gabriela Hrebikova et al. · mBio · 2017 · 64 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17

A phase <scp>II</scp> trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (<scp>GRM</scp>1) signaling, in patients with advanced melanoma

Janice M. Mehnert, Ann W. Silk, J. H. Lee et al. · Pigment Cell & Melanoma Research · 2018 · 54 citations · Full text

Medicine, Oncology, Pharmacology +17

Interobserver Reproducibility of Percent Gleason Pattern 4 in Prostatic Adenocarcinoma on Prostate Biopsies

Evita Sadimin, Francesca Khani, Mairo L. Diolombi et al. · The American Journal of Surgical Pathology · 2016 · 49 citations

Medicine, Pathology, Urology +17